ITGB6 and non-small cell lung carcinoma: In preclinical studies, the antibody component of SGN-B6A specifically targets ITGB6, without binding to other members of the alpha-V family, and exhibits in vivo activity in models of NSCLC, pancreatic cancer, pharyngeal cancer, and bladder cancer (120).